Gilead Sciences Ranks 60th in Market Activity with $11.89 Billion Trading Volume as Yeztugo Approval Drives Stock Gains

On June 20, 2025, Gilead Sciences (GILD) saw a trading volume of $11.89 billion, ranking 60th in the day's market activity. The stock rose by 0.59%, marking its second consecutive day of gains, with a total increase of 0.59% over the past two days.

Gilead Sciences recently secured FDA approval for Yeztugo, marking a significant milestone in HIV prevention as the first twice-yearly PrEP option in the U.S. This approval is supported by robust Phase 3 data, enhancing Gilead's competitive edge in the market. The approval comes at a pivotal time, potentially driving further revenue and earnings growth for the company. Over the past three years, Gilead's total shareholder return reached 93%, demonstrating strong long-term performance. This approval bolsters confidence in Gilead's ongoing product launches, particularly lenacapavir and Trodelvy, positioning them to capture larger markets and support future revenue growth. Analysts anticipate Gilead's annual revenue growth to reach 5.7% with earnings projected to hit $10.2 billion by 2028. The current share price at $97.88 indicates room for growth relative to analyst expectations, with a potential upside towards the fair value consensus at $116.77 and a bullish target at $140. This approval adds weight to these projections, corroborating the company's strategy and affirming its innovation momentum in the biopharmaceutical industry.